BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

Close to 30 new modality drugs approved in the last five years, and about 50 in registrational trials
BioCentury | Dec 14, 2016
Clinical News

NY-ESO-SPEAR T-cell therapy: Ph I/II started

BioCentury | Oct 17, 2016
Clinical News

NY-ESO SPEAR T-cell therapy: Phase I/IIa amended

BioCentury | Aug 15, 2016
Clinical News

NY-ESO SPEAR T-cell therapy: Pivotal trial hold

BioCentury | Aug 15, 2016
Finance

Serving returns

How Ally Bridge expects to build on top of WuXi arbitrage play
Items per page:
1 - 10 of 12